| Doctor Profile |
TOXIC HEAVY METALS:
SOURCES AND SPECIFIC EFFECTSPublished in the August issue of Alternative & Complementary Therapies (a magazine for doctors)
and Published in the April issue of Townsend Letter for Doctor's & Patients.Human beings have been exposed to heavy metal toxins for an immeasurable amount of time. The industrialization of the world has dramatically increased the overall environmental 'load' of heavy metal toxins, to the point that our societies are dependent upon them for proper functioning. Industry and commercial processes have actively mined, refined, manufactured, burned, and manipulated heavy metal compounds for a number of reasons. Today, heavy metals are abundant in our drinking water, air and soil due to our increased use of these compounds. They are present in virtually every area of modern consumerism-from construction materials to cosmetics, medicines to processed foods, fuel sources to agents of destruction, appliances to personal care products. It is very difficult for anyone to avoid exposure to any of the many harmful heavy metals that are so prevalent in our environment. While it does not appear that we are going to neutralize the threat of heavy metal toxicity in our communities, nor decrease our utilization of the many commercial goods that they help produce, we can take steps to understand this threat and put into action policies of prevention and treatment that may help to lessen the negative impact that these agents have on human health.
Heavy metal toxins contribute to a variety of adverse health effects. There exist over 20 different heavy metal toxins that can impact human health and each toxin will produce different behavioral, physiological, and cognitive changes in an exposed individual. The degree to which a system, organ, tissue, or cell is affected by a heavy metal toxin depends on the toxin itself and the individual's degree of exposure to the toxin. Here are presented just 5 of the many hazardous metal toxins that are commonly encountered by humans. Each of these metals affects an individual in such a way that its respective accumulation within the body leads to a decline in the mental, cognitive, and physical health of the individual. The specific sources of exposure, where the metals tend to be deposited and the adverse health effects of each metal are identified below.1. Aluminum (CAS# 7429-90-5)
Sources of exposure: Aluminum is a naturally occurring metal that has been utilized by humans for a number of years. It is the third most abumdant element in the earth's crust (approximately 8% of the crust is composed of aluminum compounds) and is apparent is small quantities (from 3-2400 ppb) in seawater (Venugopal and Luckey, 1978). Incidences of acid rain on the planet have increased the availability of aluminum to various biological systems. Acid rain is able to dissolve aluminum compounds that are naturally found in soil and rock, thus increasing their prevalence in soils and fresh- and salt-water sources. Because of this, aluminum concentrations can be seen in various fresh and salt-water marine life, and in plants that have been grown in aluminum laden soil. Humans have processed aluminum compounds for years, and its use is apparent in many different forms of industry. Because of its many industrial and commercial uses, aluminum is consumed and/or handled by many individuals on a daily basis. Today aluminum can be found in cookware, aluminum foil, dental cements, dentures, leather tanning preparations, antacids, antiperspirants, appliances, baking powder, buffered aspirin, building materials, canned acidic foods, food additives, lipsticks, construction materials (the automotive, aviation and electrical industries all use aluminum compounds for various uses), prescription and over-the-counter drugs (anti-diarrhea agents, hemorrhoid medications, vaginal douches), dialysates, vaccines, processed cheese, paints, toothpaste, fireworks and "softened" and normal tap water (ATSDR 1990, Wills and Savory, 1985). Aluminum has been found in at least 489 of the 1,416 (34%) National Priorities List (NPL) sites identified by the Environmental Protection Agency (EPA) (ATSDR 1995).Target tissues: Aluminum accumulates in the brain, muscles, liver lungs, bones, kidneys, skin, reproductive organs and stomach (ATSDR 1990, Wills and Savory, 1985). Depending on the source of exposure, aluminum can be absorbed through the gastrointestinal (GI) tract or the lungs. Absorption through the GI tract is slow, due primarily to pH factors, but once absorbed it is distributed to the bones, liver, testes, brain and soft tissues. Following aluminum inhalation, deposition occurs primarily within the lungs (Venugopal and Luckey, 1978).
Signs and Symptoms: Aluminum toxicity can produce a number of clinical signs and symptoms. Common are excessive headaches, abnormal heart rhythm, depression, numbness of the hands and feet and blurred vision (Kilburn and Warshaw, 1993). Aluminum toxicity has been shown to produce impairment in choice reaction time, long-term memory, psychomotor speed, and recall in affected individuals as compared to controls (Wills and Savory 1985). Animal studies have shown similar impairment in locomotor activity/response and spatial learning in rats receiving dietary aluminum for a period of 12 weeks (Commissaris et al., 1982). In a study conducted with patients receiving dialysis for renal failure, aluminum was believed to be a causal agent in the development of dialysis encephalopathy (or "dialysis dementia"), a special form of bone disease known as osteomalacic dialysis osteodystrophy, and anemia (Wills and Savory, 1985). In this study, individuals had been receiving concentrations of aluminum directly from their dialysate. Similarly, long-term hemo-dialysis patients have exhibited a progressive neurological syndrome that includes speech disorders, dementia, myoclonus and encephalopathy (Perl and Brody, 1980). Evidence suggests that inhaled aluminum may contribute to the development of pulmonary fibrosis and, to a lesser degree, pulmonary granulomatosis (ATSDR 1990).
Aluminum may be involved in a myriad of neurodegenerative diseases. Dr. McLaughlin, MD, F.R.C.P., a professor of physiology and medicine and the director of the Centre for Research in Neurodegenerative Diseases at the University of Toronto, states: "Concentrations of aluminum that are toxic to many biochemical processes are found in at least ten human neurological conditions"(Crapper-McLachlan 1980). Recent studies suggest that aluminum may be involved in the progression of Alzheimer's Diseae, Parkinson's disease, Guam ALS-PD complex, "Dialysis dementia", Amyotrophic Lateral Sclerosis (ALS), senile and presenile dementia, neurofibrillary tangles, clumsiness of movements, staggering when walking and an inability to pronounce words properly (Berkum 1986; Goyer 1991; Shore and Wyatt, 1983). To date, however, we do not completely understand the role that aluminum plays in the progression of such human degenerative syndromes.
Chronic aluminum exposure has contributed directly to hepatic failure, renal failure, and dementia (Arieff et al., 1979). Other symptoms that have been observed in individuals with high internal concentrations of aluminum are colic, convulsions, esophagitis, gastroenteritis, kidney damage, liver dysfunction, loss of appetite, loss of balance, muscle pain, psychosis, shortness of breath, weakness, and fatigue (ATSDR 1990). Behavioral difficulties among schoolchildren have also been correlated with elevated levels of aluminum and other neuro-toxic heavy metals (Goyer 1991). And, aluminum toxicity may also cause birth defects in new-borns (ATSDR 1990).Medical tests for aluminum screening: Blood, urine, feces, hair, and fingernails.
2. Arsenic (CAS# 7440-38-2)
Sources of exposure: The use of this toxic element in numerous industrial processes has resulted in its presence in many biological and ecological systems. Ground, surface, and drinking water are susceptible to arsenic poisoning from the use of arsenic in smelting, refining, galvanizing and power plants; environmental contaminants like pesticides, herbicides, insecticides, fungicides, desiccants, wood preservatives, and animal feed additives; and human made hazardous waste sites, chemical wastes and antibiotics. Arsenic concentrations are apparent in the air as a result of the burning of arsenic containing materials such as wood, coal, metal alloys, and arsenic waste (ATSDR 1989; Morton and Caron, 1989). Arsenic concentrations can also be found in specialty glass, defoliants, marine life (primarily fish and shellfish) and riot-control gas (Hine et al., 1977). Arsenic is present in at least 781 of the 1,300 (60%) NPL sites as identified by the EPA (RAIS 1992).Target tissues: Many arsenic compounds are readily absorbed through the GI tract when delivered orally in humans. Absorption within the lungs is dependent upon the size of the arsenic compound, and it is believed that much of the inhaled arsenic is later absorbed through the stomach after (respiratory) mucocillary clearance (ATSDR 1989). After the absorption of arsenic compounds, the primary areas of distribution are the liver, kidneys, lung, spleen, aorta, and skin. Arsenic compounds are also readily deposited in the hair and nails (U.S. EPA, 1984).
Signs and Symptoms: Arsenic is a highly toxic element that has been used historically for purposes of suicide and homicide. Its health effects are well known and multiform. Acute exposure to arsenic compounds can cause nausea, anorexia, vomiting, abdominal pain, muscle cramps, diarrhea and burning of the mouth and throat (ATSDR 1989). Garlic-like breath, malaise, and fatigue have also been seen in individuals exposed to an acute dose of arsenic, while contact dermatitis, skin lesions and skin irritation are seen in individuals whom come into direct tactile contact with arsenic compounds (Feldman et al., 1979). A large, acute oral dose has caused tachycardia, acute encephalopathy, congestive heart failure, stupor, convulsions, paralysis, coma and even death (Morton and Caron 1989). Animal studies have shown similar acute effects when arsenic compounds were delivered orally to Rhesus monkeys (Heywood and Sortwell, 1979). Repeat exposure to arsenic compounds have been shown to lead to the development of peripheral neuropathy, encephalopathy, cardiovascular distress, peripheral vascular disease, EEG abnormalities, Raynaud's phenomenon, gangrene of the lower legs ("Black foot disease"), acrocyanosis, increased vasopastic reactivity in the fingers, kidney and liver damage, hypertension, myocardial infarction, anemia and leukopenia (ATSDR 1989; Blom et al., 1985; Feldman et al., 1979; Heyman et al., 1956; Hine et al., 1977; Langerkvist et al., 1986; Morton and Caron, 1989). Other chronic effects of arsenic intoxication are skin abnormalities (darkening of the skin and the appearance of small "corns" or "warts" on the palms, soles, and torso), neurotoxic effects, chronic respiratory diseases (pharyngitits, laryngitis, pulmonary insufficiency), neurological disorders, dementia, cognitive impairment, hearing loss and cardiovascular disease (Blom et al., 1985; Kyle and Pease, 1965; Morton and Caron, 1989). A significantly higher percentage of spontaneous abortions has been shown in a population living near a copper smelting plant; lower birth weights of babies born to this same population are seen, and an abnormal percentage of male to female births is also apparent, suggesting that arsenic affects babies in utero (Nordstrom et al., 1979).
Studies have shown close associations between both inhaled and ingested arsenic and cancer rates. Cancers of the skin, liver, respiratory tract and gastrointestinal tract are well documented in regards to arsenic exposure (IARC 1980; Lee-Feldstein 1989). Several arsenic compounds have been classified by the US Environmental Protection Agency as a Class A- Human Carcinogen (IARC 1987).Medical test for arsenic screening: Urine (best), hair and fingernails.
3. Copper (CAS# 7440-50-8)
Sources of exposure: Copper occurs naturally in elemental form and as a component of many different compounds. The most toxic form of copper is thought to be that in the divalent state, cupric (Cu2+). Because of its high electrical conductivity, copper is used extensively in the manufacturing of electrical equipment and different metallic alloys. Copper is released into the environment primarily through mining, sewage treatment plants, solid waste disposal, welding and electroplating processes, electrical wiring materials, plumbing supplies (pipes, faucets, braces, and various forms of tubing), and agricultural processes (ATSDR 1990a). It is present in the air and water due to natural discharges like volcanic eruptions and windblown dust. Drinking water sources become contaminated with copper primarily because of its use in many different types of plumbing supplies. It is a common component of fungicides and algaecides, and agricultural use of copper for these purposes can result in its presence in soil, ground water, farm animals (grazing animals like cows, horses, etc.) and many forms of produce (ATSDR 1990a). Copper is also present in ceramics, jewelry, monies (coins) and pyrotechnics (ACGIH 1986). Though copper is an essential trace element required by the body for normal physiological processes, increased exposure to copper containing substances can result in copper toxicity and a wide variety of complications.Target tissues: Absorption of copper occurs through the lungs, gastrointestinal tract and skin (U.S. EPA, 1987). The degree to which copper is absorbed in the gastrointestinal tract largely depends upon its chemical state and the presence of other compounds, like zinc (U.S.A.F., 1990). Once absorbed, copper is distributed primarily to the liver, kidneys, spleen, heart, lungs, stomach, intestines, nails, and hair. Individuals with copper toxicity show an abnormally high level of copper in the liver, kidneys, brain, eyes and bones (ATSDR 1990a).
Signs and symptoms: Acute toxicity of ingested copper is characterized by abdominal pain, diarrhea, vomiting, tachycardia and a metallic taste in the mouth. Continued ingestion of copper compounds can cause cirrhosis and other debilitating liver conditions (Mueller-Hoecker et al., 1989). Inhaled copper dust or fumes can produce eye and respiratory tract irritation, headaches, vertigo, drowsiness, chills, fever, aching muscles and discoloration of the skin and hair in humans (U.S.A.F., 1990). Vineyard workers exposed to copper fumes for a long period of time developed pulmonary fibrosis and granulomas of the lungs, liver impairment and liver disease (cirrhosis, fibrosis, and various morphological changes). Similar results were obtained in animals chronically exposed to copper containing dust and fumes (Johansson et al., 1984; Stockinger 1981). Further animal studies on copper toxicity have shown varying degrees of liver and kidney damage (necrosis of the kidney; sclerosis, necrosis, and cirrhosis of the liver), decreased total weight, brain weight and red blood cell count, increased platelet counts and the presence of gastric ulcers (Kline et al., 1977; Rana and Kumar, 1978). Copper also appears to affect reproduction and development in humans and animals. Offspring of hamsters that received copper sulfate injections while pregnant exhibited increased incidences of hernias, encephalopathy, abnormal spinal curvature and spina bifida (Ferm and Hanlon, 1974). Sperm motility also appears to be compromised by the presence of copper in human spermatozoa (Battersby and Morton, 1982).
Chronic exposure to copper can produce numerous physiological and behavioral disturbances. Copper toxicity has been characterized in patients with Wilson's Disease, a genetic disorder that causes an abnormal accumulation of copper in body tissue. Wilson's disease is fatal unless treated in time. Manifestations of Wilson's Disease include brain damage and progressive demylination, psychiatric disturbances-- depression, suicidal tendencies and aggressive behavior-- hemolytic anemia, cirrhosis of the liver, motor dysfunction and corneal opacities (ATSDR 1990a; Goyer, 1991a; U.S. EPA, 1987). Some patients may also experience poor coordination, tremors, disturbed gait, muscle rigidity, and myocardial infarction (ATSDR 1990a).
Medical tests for copper screening: Blood, urine, and hair.4. Lead (CAS# 7439-92-1)
Sources of exposure: Lead is the 5th most utilized metal in the U.S. It is mined extensively in Missouri, Colorado, Idaho, and Utah and is used for the production of ammunition, bearing metals, brass materials, solder, ballasts, tubes, containers, gasoline products, ceramics, and weights (ATSDR 1993). Human exposure to lead occurs primarily through drinking water, airborne lead-containing particulates and lead-based paints. Several industrial processes create lead dust/fumes, resulting in its presence in the air. Mining, smelting and manufacturing processes, the burning of fossil fuels (especially lead-based gasoline) and municipal waste and incorrect removal of lead-based paint results in airborne lead concentrations. After lead is airborne for a period of ten days, it falls to the ground and becomes distributed in soils and water sources (fresh and salt water, surface and well water, and drinking water). However, the primary source of lead in drinking water is from lead-based plumbing materials (U.S. EPA, 1989). The corrosion of such materials will lead to increased concentrations of lead in municipal drinking water. Lead from water and airborne sources have been shown to accumulate in agricultural areas, leading to increased concentrations in agricultural produce and farm animals (ATSDR 1993). Cigarette smoke is also a significant source of lead exposure; people whom smoke tobacco, or breath in tobacco smoke, may be exposed to higher levels of lead than people whom are not exposed to cigarette smoke (RAIS 1994).Target tissues: Lead is absorbed into the body following inhalation or ingestion. Children absorb lead much more efficiently than adults do after exposure, and ingested lead is more readily absorbed in a fasting individual (U.S.EPA 1986). Over 90% of inhaled lead is absorbed directly into the blood. After lead is absorbed into the body, it circulates in the blood stream and distributes primarily in the soft tissues (kidneys, brain and muscle) and bone. Adults distribute about 95% of their total body lead to their bones, while children distribute about 73% of their total body lead to their bones (U.S. EPA, 1986a).
Signs and Symptoms: Lead is one of the most toxic elements naturally occurring on Earth. High concentrations of lead can cause irreversible brain damage (encephalopathy), seizure, coma and death if not treated immediately (U.S. EPA, 1986). The Central Nervous System (CNS) becomes severely damaged at blood lead concentrations starting at 40mcg/dL, causing a reduction in nerve conduction velocities and neuritis (ATSDR 1993). Neuropsychological impairment has been shown to occur in individuals exposed to moderate levels of lead. Evidence suggests that lead may cause fatigue, irritability, information processing difficulties, memory problems, a reduction in sensory and motor reaction times, decision making impairment, and lapses in concentration (Ehle and McKee, 1990). At blood concentrations above 70 mcg/dL, lead has been shown to cause anemia, characterized by a reduction in hemoglobin levels, and erythropoiesis-- a shortened life span of red blood cells (Goyer, 1988; US EPA 1986a). In adults, lead is very detrimental to the cardiovascular system. Occupationally exposed individuals tend to have higher blood pressure than normal controls (Pocock et al., 1984; Harlan et al., 1985; Landis and Flegal, 1988), and are at an increased risk for cardiovascular disease, myocardial infarction, and stroke (US EPA, 1990). The kidneys are targets of lead toxicity and prone to impairment at moderate to high levels of lead concentrations. Kidney disease, both acute and chronic nephropathy, is a characteristic of lead toxicity (Goyer, 1988). Kidney impairment can be seen in morphological changes in the kidney epithelium, increases in the excretion rates of many different compounds, reductions in glomerular filtration rate, progressive glomerular, arterial, and arteriolar sclerosis, and an altered plasma albumin ratio (Goyer, 1985, 1988; Landigran, 1989). Chronic nephropathy has lead to increased death rates among occupationally exposed individuals as compared to controls in studies by Selevan et al. (1975) and Cooper et al. (1985). Other signs/symptoms of lead toxicity include gastrointestinal disturbances-abdominal pain, cramps, constipation, anorexia and weight loss-immunosuppression, and slight liver impairment (ATSDR, 1993; US EPA, 1986a).
Children are susceptible to the most damaging effects of lead toxicity. Ample literature exists that shows just how damaging lead is to children. Prenatal and postnatal development are compromised significantly by the presence of lead in the body. At blood lead concentrations of 80-100 mcg/dL, severe encephalopathy occurs. Those children who survive lead-induced encephalopathy typically suffer permanent brain damage marked by mental retardation and numerous behavioral impairments. These children also suffer slower neural conduction velocities, peripheral neuropathy, cognitive impairment, and personality disorders (US EPA 1986a). Tuthill (1996) has found that hair lead levels in children were positively correlated with attention-deficit and hyperactive behavior. Numerous studies have implicated lead as a causal agent in the deterioration of cognitive functioning in children. Studies by Schroeder and Hawk (1986), Burchfield et al. (1980), Otto et al. (1981, 1982), and Munoz et al. (1993) have shown IQ deficits in children with blood lead concentrations from 6-70 mcg/dL. Longitudinal studies have given further evidence that lead affects intelligence in exposed children. Studies by Vimpani et al. (1989), McMichael et al. (1988) and Wigg et al. (1988) have shown decreased performance on intelligence tests in lead exposed school children. One study has correlated lower socio-economic status with childhood lead poisoning 50 years after lead exposure (White et al., 1993). Maternal blood lead concentrations and prenatal lead exposure appear to be strong predictors of cognitive performance in offspring. Prenatal exposure may also cause birth defects, miscarriage, spontaneous abortion and underdeveloped babies (Goyer, 1988; McMichael et al., 1988; US EPA 1986d). Lead not only appears to affect cognitive development of young children, but also other areas of neuropsychological function. Young children exposed to lead may exhibit mental retardation, learning difficulties, shortened attention spans (ADHD), increased behavioral problems (aggressive behaviors) and reduced physical growth (Bellinger, D. et al., 1990, 1992). Lead has been determined by many health experts to be the #1 threat to developing children in our industrial societies.Medical test for lead screening: Blood, urine, and hair.
5. Mercury (CAS#7439-97-6)
Sources of exposure: Mercury occurs primarily in two forms: organic mercury and inorganic mercury. Inorganic mercury occurs when elemental mercury is combined with chlorine, sulfur, or oxygen. Inorganic mercury and elemental mercury are both toxins that can produce a wide range of adverse health affects. Inorganic mercury is used in thermometers, barometers, dental fillings, batteries, electrical wiring and switches, fluorescent light bulbs, pesticides, fungicides, vaccines, paint, skin-tightening creams, vapors from spills, antiseptic creams, pharmaceutical drugs and ointments (ATSDR, 1989a). Inorganic mercury vapor is at high concentrations near chlorine-alkali plants, smelters, municipal incinerators and sewage treatment plants. The organic form occurs when mercury is combined with carbon. The most common form of organic mercury is methyl mercury, which is produced primarily by small organisms in water and soil when they are exposed to inorganic mercury. Humans also have the ability to convert inorganic mercury to an organic form once it has become absorbed into the bloodstream. Organic mercury is known to bioaccumulate-- or pass up the food chain due an organism's inability to process and eliminate it. It is found primarily in marine life (fish), and can often be found in produce and farm animals, processed grains and dairy products, and surface, salt-, and fresh water sources (ATSDR, 1989a; Brenner and Snyder, 1980). Occupational exposure to mercury containing compounds presents a significant health risk to individuals. Dentists, painters, fisherman, electricians, pharmaceutical/laboratories workers, farmers, factory workers, miners, chemists and beauticians are just some of the professions chronically exposed to mercury compounds.Target tissues: The absorption and distribution of mercury compounds depends largely upon its chemical state. Organic mercury compounds are absorbed from the gastrointestinal tract more readily than inorganic mercury compounds, with the latter being very poorly absorbed. After absorption in the gastrointestinal tract, organic mercury is readily distributed throughout the body but tends to concentrate in the brain and kidneys (Goyer, 1991b). Approximately 80% of mercury vapor is absorbed directly through the lungs and distributed primarily to the CNS and the kidneys (Friberg and Nordberg, 1973). Inorganic and organic forms of mercury have also been seen in the red blood cells, liver, muscle tissue, and gall bladder (Peterson et al., 1991, Dutczak et al., 1991, ATSDR 1989a).
Signs and symptoms: Mercury exposure can result in a wide variety of human health conditions. The degree of impairment and the clinical manifestations that accompany mercury exposure largely depend upon its chemical state and the route of exposure. While inorganic mercury compounds are considered less toxic than organic mercury compounds (primarily due to difficulties in absorption), inorganic mercury that is absorbed is readily converted to an organic form by physiological processes in the liver.
The acute ingestion of inorganic mercury salts may cause gastrointestinal disorders such as abdominal pain, vomiting, diarrhea, and hemorrhage (ATSD 1989a). Repeated and prolongued exposure has resulted in severe disturbances in the central nervous system, gastrointestinal tract, kidneys, and liver. Daivs et al. (1974) reported dementia, colitis, and renal failure in individuals chronically poisoned due to the ingestion of an inorganic mercury containing laxative. Inhaled inorganic mercury can cause a wide range of clinical complications in individuals including corrosive bronchitis, interstitial pneumonitis, renal disorders, fatigue, insomnia, loss of memory, excitability, chest pains, impairment of pulmonary function and gingivitis (Goyer 1991b, ATSDR 1989a). Chronic inhalation of inorganic mercury compounds may result in a reduction of sensory and motor nerve function, depression, visual and/or auditory hallucinations, muscular tremors, sleep disorders, alterations in autonomic function (heart rate, blood pressure, reflexes), impaired visuomotor coordination, speech disorders, dementia, coma and death (Clarkson 1989; Goyer 1991b; Fawyer et al. 1983; Piikivi and Hanninen 1989; and Ngim et al. 1992). Ngim et al. (1992) have shown that a group of dentists exposed to mercury vapors occupationally perform significantly worse in neurobehavioral tests that measure motor speed, visual scanning, visuomotor coordination and concentration, verbal memory and visual memory. Kishi et al. (1993) have found that smelter workers exposed to inorganic mercury compounds continue to experience neurological symptoms-tremors, headaches, slurred speech-senile symptoms and diminished mental capacities eighteen years after the cessation of mercury exposure.
Our understanding of the effects of methyl mercury poisoning comes primarily from epidemic poisonings in Iraq and Japan. In iraq, more than 6,000 individuals were hospitalized and 459 died as a result of methyl mercury poisoning. Adults experienced symptoms including parasthesia, visual disorders, ataxia, fatigue, tremor, hearing disorders (deafness) and coma (Bakir et al., 1973; Mottet, Shaw, and Burbacher, 1985). Neuropahtologic observations of exposed individuals have shown irreversible brain damage including neuronal necrosis, cerebral edema, gliosis, and cerebral atrophy (Mottet, Shaw, and Burbacher, 1985). Iraqi children poisoned through the consumption of methyl mercury containing food products (grains treated with mercury containing fungicides) exhibited nervous system impairment, visual and auditory disorders, weakness, marked motor and cognitive impairment, and emotional disturbances (Bakir et al., 1973; Bakir et al., 1978). Individuals in Japan experienced many of these same symptoms after the ingestion of fish containing large amounts of methyl mercury. Similarly, autopsies conducted on deceased Japanese in the Minamata Bay have shown pronounced brain lesions, cerebral atrophy, edema, and gliosis in the deeper fissures (sulci) of the brain, such as in the visual cortex (Takeuchi 1968). The Japan and Iraq epidemics have clearly established mercury as an agent that can disrupt developmental processes in the unborn, and infantile, individual. Methyl mercury can pass through the placental barrier and produce many deleterious effects on the unborn fetus (Mottet, Shaw and Burbacher 1985). Children born to mercury poisoned mothers were of smaller total weight, had decreased brain weights at birth, had fewer nerve cells in the cerebral cortex, and experienced an abnormal pattern of neuronal migration (Choi et al. 1978; Takeuchi 1968, Amin-Zake et al. 1974). Of those children that survived the epidemic, many experienced severe developmental effects like impaired motor and mental function, hearing loss, and blindness throughout their childhood (Amin-Zaki et al. 1974). Researchers have also observed a heightened incidence of cerebral palsy in children born to mothers in the Minamata Bay (Matsumoto, Koya, and Takeuchi 1965).
Mercury has recently been implicated as being a contributing factor to the increasing prevalence of autism in American children. The Autism Research Institute has focused on mercury containing vaccines (TMS) and their relationship to autism. Over 2 million individuals are affected with autism, a neurodevelopment syndrome that typically produces impairment in sociality, communication, and sensory/perceptual processes, and recent evidence has found a positive correlation between complications seen in autistics and complications seen in mercury poisoned individuals (Bernard et al., 2000). While it is difficult to ascribe causation in this case, it should not be altogether dismissed. Mercury poisoning has been implicated in the development of many other human dysfunctional states for many years. Among these are cerebral palsy, amyotrophic lateral sclerosis, Parkinson's disease, psychosis, and chronic fatigue syndrome (Adams et al., 1983; Bernard et al., 2000; Dales 1972) .We are beginning to understand the threat that heavy metal toxins are to our health. However, heavy metal toxicity is a condition that often goes overlooked in traditional medical diagnoses. While it is rare for an individual to experience a disease or health condition solely from a heavy metal toxin, it is reasonable to conclude that these toxins exert a dramatic effect on the health of an individual and contribute to the progression of many different debilitating conditions. We have seen how just 5 heavy metals and their respective compounds can adversely affect an individual's health. These effects range from simple gastrointestinal disturbances to severe emotional and cognitive disturbances. Metal toxins have the ability to impair not just a single cell or tissue, but many of the body's systems that are responsible for our behavior, mental health, and proper physiological functioning that we depend on for sustained life. If undetected, these agents can cause immeasurable pain and suffering for any afflicted individual. Fortunately, there are avenues that an affected individual can pursue to detoxify heavy metals already in their system. Popular therapies (known as chelation) today rely on intravenous (IV) solutions to help eliminate heavy metal toxins. EDTA and DMSA are two compounds that are being used for the removal of heavy metals today. These therapies have been shown to be effective, but also potentially harmful to many individuals. Alternative chelation therapies have been developed that are safer than the traditional IV therapies, and may prove to be just as effective. These therapies, popularly known as oral chelation therapies, rely on nutritional substances that have been shown to help detoxify heavy metals within the body and help support the body's overall health.
Testimonial
Parkinson like tremors / Lead plus other heavy metal toxicity
Dear Michele,
This is a note to let you and your company know how grateful
I am for the Oral Chelation Formula. For the past few years I
have had an increase in tremors of my hands. I have been on
the products now for about 21/2 months, and before I stated I
could not hold a glass of water in my left hand without significant
tremors. I am a Doctor of Naturopathic Medicine and have been
treating myself for these symptoms for some time now with
intermittent success. Since I have starting taking the Oral Chelation
from your company I have noticed a drop in the tremors to the
point that the only time I notice them at all now is when I am
extremely tired or stressed and even then they are minor.
Detoxification is a very important part of any healing process
and I feel that your company can enhance everyone's health and
healing.
Thank You,
David F. Trudeau, NMD
125 N. Locke Ave.
Farmington, NM 87401
(505)564-3558
reflex2u@outerbounds.net
(Dr. Trudeau lives in an area that has refineries and mining.
Toxic heavy metals are very prominent in the air, water, & soil).
Heavy Metal and Nutrient Element Hair Test
References:
ACGIH (American Conference of Governmental Industrial Hygienists). 1986. Copper. In: Documentation of the Threshold Limit Values and Biological Exposure Indices, 5th ed. ACGIH, Cincinnati, OH, p. 146.
Adams, C.R., Ziegler, D.K., and Lin, J.T. 1983. Mercury intoxication simulating Amyotrophic Lateral Sclerosis. JAMA 250: 642-643.
Amin-Zaki, L., S. Elhassani, M.A. Majeed, T. W. Clarkson, R.A. Doherty and M. Greenwood. 1974. Intra-uterine methylmercury poisoning. Pediatrics 54:587-595.
Arieff, A.L., Cooper, J.D., Armstrong, D., and Lazarowitz, V.C. 1979. Dementia, renal failure, and brain aluminum. Ann. Intern. Med. 90: 741-747.
Bernard, S., Enayati, A., Redwood, L., and Bistock, T. 2000. Autism: A novel form of mercury poisoning. The Aurtism Research Institute. http://www.autism.com/ari/mercury.html.
ATSDR (Agency for Toxic Substances and Disease Registry). 1989. Toxicological Profile for Arsenic. Agency for Toxic Substances and Disease Registry, U.S. Public Health Service, Atlanta, GA. ATSDR/TP-88/02.
ATSDR (Agency for Toxic Substances and Disease Registry). 1989a. Toxicological Profile for Mercury. ATSDR/U.S. Public Health Service.
ATSDR (Agency for Toxic Substances and Disease Registry). 1990. Toxicological Profile for Aluminum. Agency for Toxic Substances and Disease Registry, U.S. Public Health Service, Atlanta, GA ATSDR/TP-88/01.
ATSDR (Agency for Toxic Substances and Disease Registry). 1990a. Toxicological Profile for Copper. Prepared by Syracuse Research Corporation for ATSDR, U.S. Public Health Service under Contract 88-0608-2. ATSDR/TP-90-08.
ATSDR (Agency for Toxic Substances and disease Registry). 1993. Toxicological Profile for Lead. Update. Prepared by Clement International Corporation under contract No. 205-88-0608 for ATSDR, U.S. Public Health Service, Atlanta, GA.
Bakir, F., S. F. Kamluji, L. Amin-Zaki, et al. 1973. Methylmercury poisoning in Iraq. Science 181: 230-241.
Battersby, S., J.A. Chandler and M.S. Morton. 1982. Title not given. Fertil. Steril. 37: 230-235.
Bellinger, D.; Leviton, a.; Sloman, J. (1990) Antecedents and correlates of improved cognitive performance in children exposed in utero to low levels of lead. Environ. Health Perspect. 89:5-11.
Bellinger, D.C.; Stiles, K.M.; Needleman, H.L. (1992) Low-level lead exposure, intelligence and academic achievement: A long-term follow-up study. Pediatrics. 90:855-561.
Berkum, M.F.A. 1986. Aluminum: a role in degenerative brain disease associated with neurofibrillary degeneration" Progress in Brain Research 70: 399-409.
Blom, S.; Lagerkvist, B.; Linderholm, H. 1985. Arsenic exposure to smelter workers: clinical and neurophysiological studies. Scand. J. Work Environ. Health 11:265-270.
Brenner, R.P. and Snyder, R.D. 1980. Late Eeg findings and clinical status after organic mercury poisoning. Arch. Neurol. 37: 282-284.
Burchfiel, J.L., F.H. Duffy, P.H. Bartels and H.L. Neelleman. 1980. The combined discriminating power of quantitative electroencephalography and neuropsychologic measures in evaluating central nervous system effects of lead at low levels. In: Needleman, H.L., Ed. Low Level Lead Exposure: The Clinical Implications of Current Research. Raven Press, New York. pp. 75-89
Clarkson, T. W. 1989. Mercury. J. Am. Coll. Toxicol. 8: 1291-1295.
Commissaris, R.L., J.J. Gordon, S. Sprague, et al. 1982. Behavioral changes in rats after chronic aluminum and parathyroid hormone administration. Neurobehavior. Toxicol. Teratol. 4: 403-410.
Cooper, W.C.; Wong, O.; Kheifets, L. (1985) Mortality among employees of lead battery plants and lead-producing plants, 1947 - 1980. Scand. J. Work Environ. Health 11:331-345.
Crapper-McLachlan, D.R., and DeBoni, U. 1980. Aluminum in human brain disease-an overview." Neurotoxicology 1:3-16.
Dales, L.G. 1972. The Neurotoxicity of alkyl mercury compounds. Am. J. of Med. 53: 219-232.
Davis, L. E., J. R. Wands, S. A. Weiss, et al. 1974. Central nervous intoxication from mercurous chloride laxatives - quantitative, histochemical and ultrastructure studies. Arch. Neurol. 30: 428-431.
Dutczak, W., T. W. Clarkson, and N. Ballatori. 1991. Biliary-hepatic recycling of a xenobiotic: gallbladder absorption of methyl mercury. Amer. J. Physiol. 260: G873-G880.
Ehle, A.L.; McKee, D.C. (1990) Neuropsychological effect of lead in occupationally exposed workers: a critical review. Crit. Rev. Toxicol. 20:237-255.
Fawer, R. F., Y. De Ribaupierre, M. P. Guillemin, M. Berode, and M. Lob. 1983. Measurement of hand tremor induced by industrial exposure to metallic mercury. Br. J. Indust. Med. 40: 204-208.
Feldman, R.G.; Niles, C.A.; Kelly-Heyes, M.; Sax, D.S.; Dixon, W.J.; Thompson, D.J.; Landau, E. 1979. Peripheral neuropathy in arsenic smelter workers. Neurology 29:939-944.
Ferm, V.H. and D.P. Hanlon. 1974. Toxicity of copper salts in hamster embryonic development. Biol. Reprod. 11: 97-101.
Friberg, L. and F. Nordberg. 1973. Inorganic mercury--a toxicological and epidemiological appraisal. In: Miller, M.W. and T.W. Clarkson, eds. Mercury, mercurials and mercaptans. Charles C. Thomas Co., Springfield, Il. pp. 5-22.
Goyer, R.A. (1988) Lead. In: Handbook on Toxicity of Inorganic Compounds. H.G. Seiler and H. Sigel, eds. Marcel Dekker, Inc.: New York, pp. 359-382.
Goyer, R.A. 1991. Toxic Effects of Metals. In: Casarett and Doull's Toxicology. The Basic Science of Poisons. Fourth Edition. M.O. Amdur, J. Doull, and C.D. Klaassen, Ed. Permagon Press. pp. 662-663.
Goyer, R.A. 1991a. Toxic effects of metals. In: M.O. Amdur, J. Doull and C.D. Klaasen, Eds., Casarett and Doull's Toxicology, 4th ed. Pergamon Press, New York, NY, p. 653-655.
Goyer. R. 1991b. Toxic effects of metals. In: Amdur, M.O., J.D. Doull and C.D. Klassen, Eds. Casarett and Doull's Toxicology. 4th ed. Pergamon Press, New York. pp.623-680.
Harlan, W.R.; Landi, J.R.; Shcmouder, R.L.; Goldstein, N.G.; Harlan, L.C. (1985) Blood lead and blood pressure: relationship in the adolescent and adult US population. J. Am. Med. Assoc. 253:530-534.
Heyman, A.; Pfeiffer, J.B.; Willett, R.W.; Taylor, H.M. 1956. Peripheral neuropathy caused by arsenical intoxication. New England J. Med. 254(9): 401-409.
Heywood. R.; Sortwell, R.J. 1979. Arsenic intoxication in the rhesus monkey. Toxicol. Lett. 3:137-144.
Hine, C.H.; Pinto, S.S.; Nelson, K.W. 1977. Medical problems associated with arsenic exposure. J. Occup. Med. 19(6):391-396.
IARC (International Agency for Research on Cancer. 1980. Some metals and metallic compounds. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 23. Geneva.
IARC (International Agency for Research on Cancer (IARC). 1987. Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs Volumes 1 to 42. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, supplement 7. Geneva.
Johansson, A., T. Curstedt, B. Robertson, et al. 1984. Lung morphology and phospholipids after experimental inhalation of soluble cadmium, copper, and cobalt. Environ. Res. 34: 285-309.
Killburn, K.H. and Warshaw, R.H. 1993. Neurobehavioral testing of subjects exposed residually to groundwater contaminated from an aluminum die-casting plant and local referents. J. Toxicol. Environ. Health. 39: 483-496.
Kishi, R., R. Doi, Y. Fukuchi, H. Satoh, T. Satoh, A. Ono, et al. 1993. Subjective symptoms and neurobehavioral performances of ex-mercury miners at an average of 18 years after the cessation of chronic exposure to mercury vapor. Environ. Res. 62: 289-302.
Kline, R.D., V.W. Hays and G.L. Cromwell. 1971. Effects of copper, molybdenum and sulfate on performance, hematology and copper stores of pigs and lambs. J. Animal Sci. 33: 771-779.
Kyle, R.A.; Pease, G.L. 1965. Hematologic aspects of arsenic intoxication. New Eng. J. Med. 273(1):18-23.
Landis, J.R.; Flegal, K.M. (1988) A generalized Mantel-Haenszel analysis of the regression of blood pressure on blood lead using NHANES II data. Environ. Health Prospect. 78:35-41.
Langerkvist, B., Linderholm, H., and Nordberg, G.F. 1986. Vasopastic tendency and Raynaud's Phenomenon in smelter workers exposed to arsenic. Environ. Res. 39: 465-474.
Lee-Feldstein, A. 1989. A comparison of several measures of exposure to arsenic: matched case control study of copper smelter employees. Am. J. Epidemiol. 129:112-124.
Matsumoto, H., Koya, G., and Takeuchi, T. 1965. Fetal Minamata Disease. J. Neuropath. Exp. Neurol. 24: 563.
McMichael, A.J.; Baghurst, P.A.; Wigg, N.R.; et al. (1988) Port Pirie cohort study: environmental exposure to lead and children's ability at the age of four years. N. Engl. J. Med. 319:468-475.
Morton, W.E.; Caron, G.A. 1989. Encephalopathy: an uncommon manifestation of workplace arsenic poisoning? Am. J. Ind. Med. 15:1-5.
Mottet, N. K., C.-M. Shaw, and T. M. Bubacher. 1985. Health risks from increases in methylmercury exposure. Environ. Health Perspect. 63: 133-140.
Mueller-Hoecker, J., U. Meyer, B. Wiebecke, et al. 1988. Copper storage disease of the liver and chronic dietary copper intoxication in two further German infants mimicking Indian childhood cirrhosis. Pathol. Red. Pract. 183: 39-45.
Muñoz, H.; Romieu, I.; Palazuelos, E.; et al. (1993) Blood lead level and neurobehavioral development among children living in Mexico City. Arch. Environ. Health. 48:132-139.
Ngim, C. H., S. C. Foo, K. W. Boey, and J. Jeyaratnam. 1992. Chronic neurobehavioral effects of elemental mercury in dentists. Br. J. Ind. Med. 49: 782-790.
Nordström, S.; Beckman, L.; Nordenson, I. 1978a. Occupational and environmental risks in and around a smelter in northern Sweden. I. Variations in birth weight. Hereditas 88:43-46.
Otto, D.A., V.A. Benignus, K.E. Muller and C.N. Barton. 1981. Effects of age and body lead burden on CNS function in young children. I. Slow cortical potentials. Electroencephalogr. Clin. Neurophysiol. 52: 229-239.
Perl, D.P. and Brody, A.R. 1980. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208: 297-299.
Petersson, K., L. Dock, K. Söderling and M. Vahter. 1991. Distribution of mercury in rabbits subchronically exposed to low levels of radiolabeled methyl mercury. Pharmacol. Toxicol. 68: 464-468.
Piikivi, L., and H. Hanninen. 1989. Subjective symptoms and psychological performance of chlorine-alkali workers. Scand. J. Work Environ. Health 15: 69-74.
Pocock, S.J.; Shaper, A.G.; Ashby, D. Delves, T.; Whitehead, T.P. (1984) Blood lead concentration, blood pressure, and renal function. Br. Med. J. 289:872-874.
RAIS Toxicity Profile for Arsenic. April 1992. http://risk.lsd.ornl.gov/tox/profiles/arsenic.shtml.
RAIS Toxicity Profile for Lead. December 1994. http://risk.lsd.ornl.gov/tox/profiles/lead.shtml.
Rana, S.V.S. and A. Kumar. 1978. Simultaneous effects of dietary molybdenum and copper on the accumulation of copper in the liver and kidney of copper poisoned rats. A histochemical study. Ind. Health 18: 9-17.
Selevan, S.G.; Landrigan, P.J. Stern, F.B.; Jones, J.H. (1985) Mortality of lead smelter workers. Am. J. Epidemiol. 122:673-683.
Shore, D. and R.J. Wyatt. 1983. Aluminum and Alzheimer's disease. J. Nerv. Ment. Dis. 171: 553-558.
Stokinger, H.E. 1981. Copper. In: G.D. Clayton and E. Clayton, Eds, Patty's Industrial Hygiene and Toxicology, Vol. 2A. John Wiley & Sons, New York, NY, pp. 1620-1630.
Takeuchi, T. 1968. In: Minamata Disease (M. Kutsama Ed.), Kumamoto Univ. Press, Kumamoto, Japan. Pp141-228.
Tuthill, R.W. 1996. Hair lead levels related to children's classroom attention-deficit behavior. Arch. Environ. Health 51 (3): 214-220.
U.S. AF (U.S. Air Force). 1990. Copper. In: The Installation Program Toxicology Guide, Vol. 5. Wright-Patterson Air Force Base, Ohio, pp. 77(1-43).
U.S. EPA. 1984. Health Assessment Document for Arsenic. Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Research Triangle Park, NC. EPA 600/8-32-021F.
U.S. Environmental Protection Agency (EPA). 1986. Lead effects on cardiovascular function, early development, and stature: an addendum to EPA Air Quality Criteria for Lead (1986). In: Air Quality Criteria for Lead, Vol. I. Environmental Criteria and Assessment Office, Research Triangle Park, NC. EPA-600/8-83/028aF. Available from NTIS, Springfield, VA; PB87-142378. pp. A1-67.
U.S. EPA. 1987. Drinking Water Criteria Document for Copper. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH, for the Office of Drinking Water, Washington, DC. ECAO-CIN-417.
U.S. Environmental Protection Agency (EPA). 1989. Evaluation of the Potential Carcinogenicity of Lead and Lead Compounds. Office of Health and Environmental Assessment. EPA/600/8-89/045A.
U.S. Environmental Protection Agency (EPA). 1990. Air Quality Criteria for Lead: Supplement to the 1986 Addendum. Environmental Criteria and Assessment Office, Research Triangle Park, NC. EPA-600/8-89/049F.
Venugopal, B. and T.D. Luckey. 1978. Metal Toxicity in Mammals-2. Chemical Toxicity of Metals and Metalloids. Plenum Press. pp. 104-112.
Vimpani, G.; Baghurst, P.; McMichael, A.J.; et al. (1989) "The effects of cumulative lead exposure on pregnancy outcome and childhood development during the first four years." Presented at: Conference on Advances in Lead Research: Implications for Environmental Research. Research Triangle Park, NC, National Institute of Environmental Health Sciences, January.
White, R.F.; Diamond, R.; Proctor, S.; Morey, C.; Hu, H. (1993) Residual cognitive deficits 50 years after lead poisoning during childhood. Br. J. Ind. Med. 50:613-622.
Wigg, N.R.; Vimpani, G.V.; McMichael, A.J.; et al. (1988) Port Pirie cohort study: childhood blood lead and neuropsychological development at age two years. J. Epidemiol. Commun. Health. 42:213-219.
Willis, M.R. and Savory, J. 1985. Water content of aluminum, dialysis dementia, and osteomalacia. Env. Health. Persp. 63: 141-147.
We welcome your questions be they by phone or email.
Your health is a vitally important and we are happy to answer your questions about oral chelation and its advantages for you.
Please don't hesitate to contact us at
1-800-800-1285 Monday to Friday 9:00AM to 5:00 PM Pacific Standard Time
925-855-1262
Fax 925-314-7798P.O. Box 128
Alamo, California
USA
94507
Order the highest quality:
Oral Chelation Formula
Liver Support Formula
DigestiveSupport Formula
Recommend This Site To Someone You Love
Pharmaceutical Quality, FDA approved manufacturing plant and procedures
Act Now For Your Health!
Privacy
Extreme Health takes your personal privacy seriously. Because we value our customer relationship with you, we do not sell customer information or share it with organizations.
Thank you for choosing Extreme Health. We appreciate your business.
______________________________________________________________________
Disclaimer:All information on this site is provided for informational purposes only! By no means is any information presented herein intended to substitute for the advice provided to you by your own physician or health care provider. You should not use any information contained in our site to self-diagnose or personally treat any medical condition or disease or prescribe any medication. If you have or suspect you have a medical condition you are urged to contact your personal health care provider immediately. All health supplements or products purchased in this site contain clearly labeled product packaging, which must be read to ensure proper use. All information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. It has not been conclusively established that oral chelation is an effective treatment or cure for any disease or condition or that it actually prevents or mitigates such harm. However, Extreme Health, Inc. believes that the use of its products is a responsible precautionary stop for those people who are informed and concerned about such matters.
The National Institute of Health recently began a five-year double blind study on the effects of intravenous chelation. Since qualified doctors have offered their patients chelation treatments for over thirty years, we all look forward to these results. Extreme Health has a doctor's label featuring the exact oral chelation formula that we sell directly to the public. We've sold this to doctors for over four years!
If any customer is not satisfied with Extreme Health's Oral Chelation Formula we will refund the purchase price upon return of the unused product and proof of purchase to Extreme Health, Inc.
